Obstruction of extrahepatic bile ducts by lymphocytes is regulated by IFN-gamma in experimental biliary atresia.
The etiology and pathogenesis of bile duct obstruction in children with biliary atresia are largely unknown. We have previously reported that, despite phenotypic heterogeneity, genomic signatures of livers from patients display a proinflammatory phenotype. Here, we address the hypothesis that production of IFN-gamma is a key pathogenic mechanism of disease using a mouse model of rotavirus-induced biliary atresia. We found that rotavirus infection of neonatal mice has a unique tropism to bile duct cells, and it triggers a hepatobiliary inflammation by IFN-gamma-producing CD4(+) and CD8(+) lymphocytes. The inflammation is tissue specific, resulting in progressive jaundice, growth failure, and greater than 90% mortality due to obstruction of extrahepatic bile ducts. In this model, the genetic loss of IFN-gamma did not alter the onset of jaundice, but it remarkably suppressed the tissue-specific targeting of T lymphocytes and completely prevented the inflammatory and fibrosing obstruction of extrahepatic bile ducts. As a consequence, jaundice resolved, and long-term survival improved to greater than 80%. Notably, administration of recombinant IFN-gamma led to recurrence of bile duct obstruction following rotavirus infection of IFN-gamma-deficient mice. Thus, IFN-gamma-driven obstruction of bile ducts is a key pathogenic mechanism of disease and may constitute a therapeutic target to block disease progression in patients with biliary atresia.
Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Ohio 45229-3039, USA.
Pranavkumar
P
Shivakumar
Kathleen M
KM
Campbell
Gregg E
GE
Sabla
Alexander
A
Miethke
Greg
G
Tiao
Monica M
MM
McNeal
Richard L
RL
Ward
Jorge A
JA
Bezerra
D000818:Animals; D000831:Animals, Newborn; D000998:Antiviral Agents / Q000627:therapeutic use*; D017734:Bile Ducts, Extrahepatic / Q000473:pathology*; D001656:Biliary Atresia / Q000276:immunology / Q000473:pathology / Q000628:therapy* / Q000821:virology; D002779:Cholestasis / Q000209:etiology* / Q000473:pathology; D004195:Disease Models, Animal; D007371:Interferon-gamma / Q000627:therapeutic use*; D008214:Lymphocytes / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D011994:Recombinant Proteins; D012401:Rotavirus / Q000472:pathogenicity; D012400:Rotavirus Infections / Q000473:pathology
D000998:Antiviral Agents; D011994:Recombinant Proteins; D007371:Interferon-gamma